Sivakumar Jayaraman has stepped into the role of General Manager at Granules India Limited, marking a significant milestone in his accomplished career within the pharmaceutical industry. With over 20 years of cross-functional experience across procurement, supply chain, and strategic sourcing, Sivakumar brings deep industry insights and a global outlook to his new leadership position at the Hyderabad-based pharmaceutical major.
At Granules India, Sivakumar leads strategic sourcing initiatives, overseeing procurement operations for APIs, excipients, packaging materials, and clinical services across global R&D centers. His focus lies in building resilient supply chains through market intelligence, alternate vendor development, supplier risk mitigation, and the execution of commercial and licensing agreements. Known for his techno-commercial expertise, he plays a critical role in enabling innovation and profitability through robust procurement frameworks.
Prior to this, Sivakumar served as DGM – SCM and Head of Direct Procurement at Biological E. Limited, where he led procurement functions across five manufacturing plants, driving operational excellence and strategic alignment with business goals. His decade-long tenure at Dr. Reddy’s Laboratories, where he rose to the role of Associate Director – Strategic Sourcing, shaped his deep command over outsourcing, budgeting, CRO management, and global contract negotiations.
His earlier contributions across Cipla, Chemplast Sanmar, and JK Pharmachem reflect a strong foundation in technology transfer, scale-up processes, and production optimization. Academically, he holds a B.Tech in Chemical Engineering from Anna University and a PG Diploma in Supply Chain Management from NMIMS, adding academic rigor to his hands-on experience.
With a track record of building long-term vendor relationships and leading multifunctional procurement teams, Sivakumar Jayaraman’s joining further strengthens Granules India’s commitment to operational agility and global sourcing excellence. His leadership is expected to drive innovation, cost optimization, and sustainable growth in an increasingly competitive pharmaceutical landscape.